← All Vaxcyte, INC filings

Vaxcyte, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PCVX
Vaxcyte, INC
10-K: Vaxcyte Advances VAX-31 to Phase 3, Secures $632.5M Funding
Vaxcyte initiated multiple Phase 3 trials for its 31-valent pneumococcal vaccine candidate, VAX-31, following positive Phase 1/2 results and expanded Breakthrough Therapy Designation, while also raising $632.5 million in a public offering.
NASDAQ
PCVX
Vaxcyte, INC
10-K: Vaxcyte Announces Positive Phase 1/2 Data for VAX-31 and Advances Pipeline
Vaxcyte reports positive clinical trial results and progresses its vaccine pipeline, including a breakthrough therapy designation for VAX-31.
NASDAQ
PCVX
Vaxcyte, INC
10-K: Vaxcyte Inks Manufacturing Deal with Lonza, Secures Key Supply Chain Component
Vaxcyte has entered into a significant manufacturing agreement with Lonza, securing a dedicated suite for production and gaining control over a crucial supply chain element.